FERMAGATE ANHYDROUS

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	CO3.2Fe.4Mg.12HO
Molecular Weight	473.007
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Fe+3].[Fe+3].[O-]C([O-])=O

InChI

InChIKey=HBHWBHDZABTVTA-UHFFFAOYSA-A

InChI=1S/CH2O3.2Fe.4Mg.12H2O/c2-1(3)4;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;12*1H2/q;2*+3;4*+2;;;;;;;;;;;;/p-14

HIDE SMILES / InChI

Molecular Formula	Mg
Molecular Weight	24.305
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Fe
Molecular Weight	55.845
Charge	3
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	CO3
Molecular Weight	60.0089
Charge	-2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	HO
Molecular Weight	17.0073
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67541219 | https://www.ncbi.nlm.nih.gov/pubmed/19158369 | http://www.opkorenal.com/pipeline/product_candidates.html

FERMAGATE is a phosphate binder with phosphate plasma levels lowering activity. It is in Phase 3 development in the US and in Europe for the treatment of hyperphosphatemia in dialysis patients. It is made up of magnesium and ferric iron atoms held in an insoluble, rigid, crystalline-layered structure, with carbonate groups lying between the layers. Upon oral administration, the carbonate ions in FERMAGATE are exchanged for free phosphate ions released from food in the gastrointestinal tract; thereby, strongly binding phosphate. This inhibits phosphate uptake and preventing hyperphosphatemia.

Originator

Approval Year

PubMed

Title	Date	PubMed
Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?	2015-04	25815172
Iron-magnesium hydroxycarbonate (fermagate): a novel non-calcium-containing phosphate binder for the treatment of hyperphosphatemia in chronic hemodialysis patients.	2009-02	19158369
Different Mg to Fe ratios in the mixed metal MgFe hydroxy-carbonate compounds and the effect on phosphate binding compared with established phosphate binders.	2002-01	11782897

Sample Use Guides

In Vivo Use Guide

Recommended daily dose: 3000 mg, three pills per day.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:02:14 GMT 2025` Edited by `admin` on `Mon Mar 31 21:02:14 GMT 2025`
Record UNII	4VNO5L64GQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FERMAGATE ANHYDROUS

Common Name

English

DIIRON(III) TETRAMAGNESIUM CARBONATE DODECAHYDROXIDE

Preferred Name

English

IRON MAGNESIUM CARBONATE HYDROXIDE (FE2MG4(CO3)(OH)12)

Common Name

English

FERRATE (FE(OH)63-), (OC-6-11)-, MAGNESIUM CARBONATE (2:4:1)

Common Name

English

Code System Code Type Description

FDA UNII

4VNO5L64GQ